Two Sigma Advisers
VRCA icon

Two Sigma Advisers’s Verrica Pharmaceuticals VRCA Stock Holding History

Two Sigma Advisers’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44,430
Closed -$369K – 2109
2025
Q4 		$369K Buy
+44,430
New +$246K ﹤0.01% 1902
2023
Q3 		– Sell
-2,630
Closed -$152K – 2588
2023
Q2 		$152K Buy
2,630
+540
+26% +$32.8K ﹤0.01% 2142
2023
Q1 		$136K Sell
2,090
-1,200
-36% -$72.6K ﹤0.01% 2333
2022
Q4 		$90.5K Buy
3,290
+2,030
+161% +$54.2K ﹤0.01% 2309
2022
Q3 		$37K Buy
+1,260
New +$43.2K ﹤0.01% 2395

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers's VRCA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Verrica Pharmaceuticals (VRCA) in Q1 2026, closing a stake of 44,430 shares — an estimated $369K sold.

Two Sigma Advisers first reported a position in VRCA in Q3 2022 and held it in 5 quarters. The position peaked at $369K in Q4 2025. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • Two Sigma Advisers reported no remaining Verrica Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 44,430 Verrica Pharmaceuticals shares in Q1 2026, an estimated $369K.
  • Two Sigma Advisers first reported a position in Verrica Pharmaceuticals in Q3 2022 and held it in 5 quarters.
  • Two Sigma Advisers's Verrica Pharmaceuticals position peaked at $369K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.